http://orcid.org/0000-0001-9384-8008
References
- World Health Organization. Global report on diabetes. Geneva: World Health Organization; 2016 [ cited 2017 Jul 31]. Available from: http://www.who.int/diabetes/global-report/en/
- Centers for Disease Control and Prevention. National diabetes statistics report: estimates of diabetes and its burden in the United States. Center for Disease Control and Prevention; 2014 [ cited 2017 Jul 31]. Available from: https://www.cdc.gov/diabetes/pdfs/library/diabetesreportcard2014.pdf
- Boyle JP, Thompson TJ, Gregg EW, et al. Projection of the year 2050 burden of diabetes in the US adult population: dynamic modeling of incidence, mortality, and prediabetes prevalence. Popul Health Metrics. 2010;8:29. DOI:10.1186/1478-7954-8-29
- Middleton J. The effect of case management on glycemic control in patients with type 2 diabetes. Case Manag. 2003;14(6):43–47. DOI:10.1016/S1061925903002650
- American Diabetes Association. Standards of medical care in diabetes – 2009. Diabet Care. 2009 Jan;Suppl 1:S1–S2, 32. Available from: https://doi.org/10.2337/dc09-S001
- American Diabetes Association. Executive summary: standards of medical care in diabetes – 2013. Diabet Care. 2013;Suppl 1:S4–S10, 36. Available from: https://doi.org/10.2337/dc13-S004
- U.S. Food and Drug Administration. FDA approves Jardiance to treat type 2 diabetes. Press Release. 2014 Aug 1 [ cited 2016 Aug 10]. Available from: www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm407637.htm
- U.S. Food and Drug Administration. FDA drug safety communication: FDA warns that SGLT2 inhibitors for diabetes may result in a serious condition of too much acid in the blood. Safety Announcement. 2015 [ cited 2017 Jul 31]. Available from: https://www.fda.gov/Drugs/DrugSafety/ucm446845.htm
- Häring H, Merker L, Seewaldt-Becker E, et al. on behalf of the EMPA-REG METSU Trial Investigators. Empagliflozin as add-on to metformin plus sulfonylurea in patients with type 2 diabetes. A 24-week, randomized, double-blind, placebo-controlled trial. Diabet Care. 2013;36(11):3396–3404. DOI:10.2337/dc12-2673
- Pieber TR, Famulla S, Eilbracht J, et al. Empagliflozin as adjunct to insulin in patients with type 1 diabetes: a 4‐week, randomized, placebo controlled trial (EASE-1). Diabet Obes Metabol. 2015;17(10):928–935. DOI:10.1111/dom.12494
- Roden M, Merker L, Christiansen AV, et al. Safety, tolerability and effects on cardiometabolic risk factors of empagliflozin monotherapy in drug-naïve patients with type 2 diabetes: a double-blind extension of a Phase III randomized controlled trial. Cardiovasc Diabetol. 2015;14:154. DOI:10.1186/s12933-015-0314-0
- DeFronzo RA, Davidson JA, Del Prato S. The role of the kidneys in glucose homeostasis: a new path towards normalizing glycaemia. Diabet Obes Metabol. 2012;14:5–14. DOI:10.1111/j.1463-1326.2011.01511.x
- Hedrington MS, Davis SN. The role of empagliflozin in the management of type 2 diabetes by patient profile. Ther Clin Risk Manage. 2015;11:739–749. DOI:10.2147/TCRM.S71762
- Baker WL, Smyth LR, Riche DM, et al. Effects of sodium-glucose co-transporter 2 inhibitors on blood pressure: a systematic review and meta-analysis. J Am Soc Hypertens. 2014;8:262–275. DOI:10.1016/j.jash.2014.01.007
- U.S. Food and Drug Administration. FDA approves Jardiance to reduce cardiovascular death in adults with type 2 diabetes. FDA News Release. 2016 Dec 2 [ cited 2017 Jul 31]. Available from: https://www.fda.gov/newsevents/newsroom/pressannouncements/ucm531517.htm.
- Nishimura R, Tanaka Y, Koiwai K, et al. Effect of empagliflozin monotherapy on postprandial glucose and 24-hour glucose variability in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled, 4-week study. Cardiovasc Diabetol. 2015;14:11. DOI:10.1186/s12933-014-0169-9
- Peters AL, Buschur EO, Buse JB, et al. Euglycemic diabetic ketoacidosis: a potential complication of treatment with sodium-glucose cotransporter 2 inhibition. Diabet Care. 2015;38(9):1687–1693. DOI:10.2337/dc15-0843
- Chai PR, Bonney C, Blohm E, et al. Canagliflozin-associated diabetic ketoacidosis: a case report. Toxicol Commun. 2017;1:2–5. DOI:10.1080/24734306.2017.1331604
- Ferrannini E, Muscelli E, Frascerra S, et al. Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients. J Clin Invest. 2014;124:499–508. DOI:10.1172/JCI72227
- Ogawa W, Sakaguchi K. Euglycemic diabetic ketoacidosis induced by SGLT2 inhibitors: possible mechanism and contributing factors. J Diabet Invest. 2016;7(2):135–138. DOI:10.1111/jdi.12401
- Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30(2):239–245. DOI:10.1038/clpt.1981.154.
- Friesecke S, Abel P, Roser M, et al. Outcome of severe lactic acidosis associated with metformin accumulation. Crit Care. 2010;14(6):R226. DOI:10.1186/cc9376. Epub 2010 Dec 20.